Brown Todd K, Caragea Marc A, Beckwith Margaret, Ni Amelia, Chen Ling, Woodworth Tyler, Blatt Michael, Cheney Cole, Carson Daniel, Kuo Keith, Randall Dustin, Huang Emily Y, Carefoot Andrea, Mills Megan, Cooper Amanda N, Przybysz Allison Glinka, Burnham Taylor, Conger Aaron M, McCormick Zachary L
School of Medicine, University of Utah, Salt Lake City, UT, USA.
Department of Physical Medicine and Rehabilitation, University of Utah School of Medicine, Salt Lake City, UT, USA.
Interv Pain Med. 2025 Jan 9;4(1):100539. doi: 10.1016/j.inpm.2024.100539. eCollection 2025 Mar.
Evaluate the effectiveness of genicular nerve radiofrequency ablation (GNRFA) for chronic knee pain using the Patient-Reported Outcomes Measurement Information System Global Health, Physical Health score (PROMIS-GH-PH).
Patients who underwent GNRFA at a tertiary academic center were identified by CPT code query and contacted for consent. Demographic, clinical, and procedural characteristics were collected from the electronic medical record of participants with baseline PROMIS-GH-PH scores. Outcome data were collected by standardized telephone survey. Treatment success was defined as a ≥2.3-point improvement in PROMIS-GH-PH score (the minimal clinically important difference [MCID]). Predictor variables of PROMIS score change were evaluated using univariate and multivariate linear regression analyses.
32 patients (65.6 % female; 63.7 ± 10.7 years of age) met eligibility criteria and consented to be included in the study. In this cohort, 56.3 % (18/32; 95 % CI: 37.7-73.6) of patients reported improvement ≥ MCID on PROMIS-GH-PH at a mean follow-up time of 21.5 ± 10.6 months. Linear regression analysis demonstrated that patients who never smoked and those with a Kellgren-Lawrence (KL) osteoarthritis grade of 4 had significantly greater PROMIS-GH-PH score improvements at follow-up compared to current or former smokers and patients with KL grades of 0-3, respectively.
In this real-world cross-sectional cohort study, over 56 % of participants experienced improvment ≥ MCID on PROMIS-GH-PH after undergoing GFRNA for chronic knee pain. Non-smoking status and radiographically severe osteoarthritis were associated with greater PROMIS-GH-PH score improvements from baseline.
使用患者报告结局测量信息系统总体健康、身体健康评分（PROMIS-GH-PH）评估膝神经射频消融术（GNRFA）治疗慢性膝关节疼痛的有效性。
通过现行程序编码查询识别在一家三级学术中心接受GNRFA治疗的患者，并联系他们征求同意。从参与者的电子病历中收集人口统计学、临床和手术特征以及基线PROMIS-GH-PH评分。通过标准化电话调查收集结局数据。治疗成功定义为PROMIS-GH-PH评分提高≥2.3分（最小临床重要差异[MCID]）。使用单变量和多变量线性回归分析评估PROMIS评分变化的预测变量。
32例患者（65.6%为女性；年龄63.7±10.7岁）符合纳入标准并同意参与本研究。在该队列中，56.3%（18/32；95%CI：37.7-73.6）的患者在平均21.5±10.6个月的随访时间内报告PROMIS-GH-PH改善≥MCID。线性回归分析表明，与目前或既往吸烟者以及Kellgren-Lawrence（KL）骨关节炎分级为0-3级的患者相比，从不吸烟的患者以及KL骨关节炎分级为4级的患者在随访时PROMIS-GH-PH评分改善显著更大。
在这项真实世界横断面队列研究中，超过56%的参与者在接受GFRNA治疗慢性膝关节疼痛后PROMIS-GH-PH改善≥MCID。非吸烟状态和影像学上严重的骨关节炎与从基线开始更大的PROMIS-GH-PH评分改善相关。
